|
Placebo
|
Maraviroc
300 mg BID
|
Pvalue
|
---|
ACR components
| | | |
Tender/painful joint count
|
-3.41 (1.19) [n = 33]
|
-4.89 (0.84) [n = 77]
|
0.294
|
Swollen joint count
|
-3.43 (0.95) [n = 33]
|
-3.48 (0.66) [n = 77]
|
0.966
|
Patient's assessment of arthritis pain
|
-6.09 (4.06) [n = 33]
|
-8.30 (2.85) [n = 77]
|
0.644
|
Patient's global assessment of arthritis
|
-6.78 (4.06) [n = 33]
|
-8.55 (2.88) [n = 76]
|
0.712
|
Physician's global assessment of arthritis
|
-0.36 (0.15) [n = 32]
|
-0.49 (0.11) [n = 75]
|
0.490
|
HAQ-DI
|
-0.06 (0.13) [n = 20]
|
-0.18 (0.08) [n = 55]
|
0.396
|
SF-36 version 2 (acute)
| | | |
Physical component summary
|
4.81 (1.65) [n = 19]
|
3.14 (1.04) [n = 53]
|
0.344
|
Mental component summary
|
0.61 (2.25) [n = 19]
|
1.17 (1.41) [n = 53]
|
0.818
|
- ACR, American College of Rheumatology; BID, twice daily; FAS, full analysis set; HAQ-DI, health assessment questionnaire-disability index; LOCF, last observation carried forward; SEM, standard error of the mean; SF-36, Short Form-36 Health Survey.